Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer

British Journal of Clinical Pharmacology

Volumn 81, Issue 5, 2016, Pages 941-948

  Bernadou, Guillemette ^a,b   Campone, Mario ^c   Merlin, Jean Louis ^d,e,f   Gouilleux Gruart, Valérie ^a,b   Bachelot, Thomas ^g   Lokiec, François ^h   Rezai, Keyvan ^h   Arnedos, Monica ⁱ   Diéras, Véronique ⁱ   Jimenez, Marta ^j   Paintaud, Gilles ^a,b   Ternant, David ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^f Cancer Support Unit Institut de Cancérologie de Lorraine Alexis Vautrin   (France)

^g CENTRE LÉON BÉRARD   (France)

^h INSTITUT CURIE   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UNICANCER   (France)

more..

Author keywords

breast cancer; pharmacokinetics; population PK modelling; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CENTRAL VOLUME OF DISTRIBUTION; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INFUSION; ECHOMAMMOGRAPHY; ELIMINATION HALF-LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIPHERAL VOLUME OF DISTRIBUTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR INVASION; TUMOR VOLUME; BREAST NEOPLASMS; CLINICAL TRIAL; HALF LIFE TIME; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EVEROLIMUS; FEMALE; HALF-LIFE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; TRASTUZUMAB; TUMOR BURDEN; ULTRASONOGRAPHY, MAMMARY;

EID: 84959881968     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12875     Document Type: Article

References (24)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. Hudis CA,. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
3. Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, Ohta M, Fujii H, Sasaki Y, Niwa T, Tajima T,. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 1999; 81: 1419-25.
4. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P,. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-71.
5. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P,. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005; 56: 361-9 Epub 2005 May 3.
6. Fukushima Y, Charoin J, Brewster M, Jonsson E,. Population pharmacokinetic analysis of trastuzumab (Herceptin®) based on data from three different dosing regimens. PAGE 2007; 16: Abstract 1121. Available at [www.page-meeting.org/?abstract=21] (last accessed 09 February 2016).
7. Leyland-Jones B, Colomer R, Trudeau ME, Wardley A, Latreille J, Cameron D, Cubedo R, Al-Sakaff N, Feyereislova A, Catalani O, Fukushima Y, Brewster M, Cortes J,. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol 2010; 28: 960-6.
8. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P,. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21: 3965-71 Epub 2003 Sep 24.
9. Cosson VF, Ng VW, Lehle M, Lum BL,. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 2014; 73: 737-47.
10. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ,. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63: 548-61 Epub 2006 Nov 10.
11. Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, Louis E, Paintaud G,. Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn's disease. Clin Pharmacokinet 2014; 2014: 17.
12. Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau-Gervais E, Watier H, Goupille P, Paintaud G, Mulleman D,. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol 2013; 2013: 12313.
13. Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, Le Pape A, Bardos P, Paintaud G, Cartron G,. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2008; 24: 24.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
15. Comets E, Brendel K, Mentre F,. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66 Epub 2008 Jan 22.
16. Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA,. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 2005; 45: 468-76.
17. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-32.
18. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 633-59. doi: 10.2165/11535960-000000000-00000.
19. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M,. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 2013; 52: 83-124.
20. Gibiansky L, Gibiansky E,. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn 2009; 36: 341-51. doi: 10.1007/s10928-009-9125-9 Epub 2009 July 4.
21. Morell A, Terry WD, Waldmann TA,. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49: 673-80.
22. Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, Zaja F, Montagna M, Morra E, Lazzarino M,. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 2005; 27: 785-92.
23. Ng CM, Bruno R, Combs D, Davies B,. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792-801.
24. Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M,. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012; 119: 3276-84.